Clostridium News and Research

RSS

Acid reducing drugs could raise risk of C. diff diarrhea

U.S. health regulators, the Food and Drugs Administration (FDA), have announced that ulcer drugs such as AstraZeneca Plc's blockbuster Nexium could increase the risk of Clostridium difficile-associated diarrhea (CDAD).

9 Feb 2012

Study identifies norovirus as major cause of all infection outbreaks in U.S. hospitals

Norovirus, a pathogen that often causes food poisoning and gastroenteritis, was responsible for 18.2 percent of all infection outbreaks and 65 percent of ward closures in U.S. hospitals during a two-year period, according to a new study published in the February issue of the American Journal of Infection Control (AJIC), the official publication of APIC - the Association for Professionals in Infection Control and Epidemiology.

1 Feb 2012

FDA clears Meridian Bioscience's new Clostridium difficile assay

Meridian Bioscience, Inc., Cincinnati, Ohio today announced it has received FDA clearance for a new Clostridium difficile assay, ImmunoCard C. difficile GDH.

27 Dec 2011

FDA approves modernized labeling for ViroPharma's Vancocin Capsules

ViroPharma Incorporated today announced the modernization of labeling for Vancocin (vancomycin hydrochloride, USP) Capsules made effective through the U.S. Food and Drug Administration's (FDA) approval of a supplemental new drug application.

15 Dec 2011

Auxilium initiates XIAFLEX phase IIa trial in Frozen Shoulder syndrome

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the first patient has been dosed in its open-label phase IIa trial of XIAFLEX (collagenase clostridium histolyticum) for the treatment of idiopathic adhesive capsulitis of the shoulder, also known as Frozen Shoulder syndrome.

1 Dec 2011

Botulism toxins could be re-engineered for treating RA, asthma, psoriasis

The most poisonous substance on Earth - already used medically in small doses to treat certain nerve disorders and facial wrinkles - could be re-engineered for an expanded role in helping millions of people with rheumatoid arthritis, asthma, psoriasis and other diseases, scientists are reporting. Their study appears in ACS' journal Biochemistry.

1 Dec 2011

CDC launches new antibiotic tracking system

The Centers for Disease Control and Prevention is launching a new antibiotic tracking system allowing hospitals to monitor antibiotic use electronically, make better decisions about how to improve use, and compare themselves to other hospitals. Before now, CDC was only able to track antibiotic use in doctors' offices.

15 Nov 2011

Great Basin seeks FDA 510(k) approval for C. difficile molecular diagnostic test

Great Basin Corporation, a privately held life sciences company developing sample-to-result molecular diagnostic solutions, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its first molecular diagnostic test for Clostridium difficile (C. diff).

14 Nov 2011

Study finds multidrug-resistant Acinetobacter baumannii in 48% of infected patient rooms

Multidrug-resistant Acinetobacter baumannii (MDR-AB) was found in the environment of 48 percent of the rooms of patients colonized or infected with the pathogen, according to a new study published in the November issue of the American Journal of Infection Control, the official publication of APIC - the Association for Professionals in Infection Control and Epidemiology.

2 Nov 2011

Colonoscopic FMT effective in treating IBD, C.difficile-associated diarrhea

Growing evidence for the effectiveness of fecal microbiota transplants as a treatment for patients with recurrent bouts of Clostridium difficile (C.difficile) associated diarrhea is presented in three studies -- including a long-term follow-up of colonoscopic fecal microbiota transplant (FMT) for recurrent C. difficile Infection that included 77 patients from five different states-- unveiled today at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC.

1 Nov 2011

Nursing home residence may allow for 'on-admission' prediction model of C. difficile infection severity

Antibiotics may not be the only risk factor associated with community-acquired Clostridium difficile infection, indicating that other undefined causes of the potentially life-threatening infection may exist and could also predict whether or not a patient will require hospitalization, according to the results of the study, "Predictors of Hospitalization in Community-Acquired Clostridium difficile Infection."

31 Oct 2011

'Good bugs' promising against ulcerative colitis, psoriasis, chronic fatigue syndrome

In four different studies presented at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC, researchers explored the effectiveness of probiotics for antibiotic-associated diarrhea; as an anti-inflammatory agent for patients with ulcerative colitis, psoriasis and chronic fatigue syndrome; and for people with abdominal discomfort and bloating who have not been diagnosed with a functional bowel disorder, such as irritable bowel syndrome (IBS).

31 Oct 2011

Specific metabolic disturbances precede children's progression to Type 1 diabetes

New potential avenues for early disease detection and prevention: A study led by Matej Orešič from VTT Technical Research Centre of Finland suggests that autoimmune diabetes is preceded by diminished gut microbial diversity of the Clostridium leptum subgroup, elevated plasma leptin and enhanced glucose-stimulated insulin secretion.

29 Oct 2011

Prevention training critical to reduction of hospital infection rates

Infections picked up in hospital affect almost a third of patients in intensive care, and kill 44% of those people. Given that some infectious agents can linger for weeks or months it is increasingly important that staff awareness of the problem is improved and that training in infection prevention across the National Health Service and in private healthcare is expanded, according to researchers at the University of Northampton.

15 Oct 2011

Four companies receive NIAID contracts to develop broad-spectrum therapeutics

Four companies are to develop broad-spectrum therapeutics-antibiotics, antivirals and an antitoxin-to prevent or treat diseases caused by multiple types of bacteria or viruses, under contracts awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

14 Oct 2011

Thomson Reuters launches Infection Xpert solution

Thomson Reuters, a global provider of information for healthcare professionals, has launched Infection Xpert — a clinical intelligence dashboard that helps infection preventionists (IPs) manage and reduce hospital-acquired infections (HAIs), capture and submit mandated infection reporting metrics, and analyze hospital infection data to improve patient safety.

12 Oct 2011

Virginia Bioinformatics Institute releases upgraded ENISI software

Researchers with the Virginia Bioinformatics Institute at Virginia Tech have released an upgrade to the institute's ENteric Immunity SImulator (ENISI) software, which models immune responses to beneficial and harmful bacteria that enter the gastrointestinal tract of mice, pigs, and humans.

7 Oct 2011

Cubist plans to move CB-183,315 into Phase 3 trial for treatment of CDAD

Cubist Pharmaceuticals, Inc. today announced it plans to move CB-183,315, being studied for the treatment of a severe and sometimes life-threatening diarrhea caused by Clostridium difficile known as C. difficile-associated diarrhea, or CDAD, into late-stage trials.

29 Sep 2011

Researchers discover cell receptor for CDT toxin of C. difficile bacterium

A research group led by Freiburg pharmacologist Prof. Dr. Klaus Aktories and their American colleagues have discovered the cell receptor for the toxin CDT of the bacterium Clostridium difficile.

27 Sep 2011

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhea.

26 Sep 2011